Avalyn Pharma debuted on Nasdaq on April 30 under the ticker “AVLN” with a $300 million IPO, far above its original $180 million goal. The biotech sold 16.6 million shares at $18 each, the top of its $16‑$18 range, and underwriters hold an option for another 2.5 million shares that would add about $45 million. Avalyn entered 2026 with $138.4 million in cash and expects to spend roughly $150 million moving AP01, its inhaled version of pirfenidone (Esbriet), into phase 3. Another $90 million is headed to AP02, an inhaled nintedanib (Ofev/Vargatef) program, and $10 million will bring AP03, a preclinical inhaled combination of both agents, into the clinic. The company employs 51 people, led by CEO Lyn Baranowski, previously of Pearl Therapeutics.
Investor enthusiasm for Avalyn’s launch underscores continuing appetite for reformulation plays, particularly those giving proven molecules a new delivery route. The inhaled approach directly targets the lung, promising lower systemic exposure and better tolerability for idiopathic pulmonary fibrosis. IPO demand at the high end of the range tells its own story: buyers appear more comfortable with a pipeline built on known actives. It also points to a thaw in specialty biotech funding after the thin 2025 calendar, suggesting liquidity is trickling back into later‑stage stories. SpyGlass Pharma and Veradermics have posted similar signs this year, and that pattern looks real, not just coincidence.
If Avalyn demonstrates improved safety or adherence, payers could classify its inhaled drugs as incremental but clinically useful, especially given the high chronic‑care costs of pulmonary fibrosis. That prospect puts mild pressure on Esbriet and Ofev brands as they edge toward generic timelines. The mixed data so far keep expectations in check, but the capital now allows Avalyn to push quickly, or not. A fast pivot to pivotal trials would show confidence. A stall would test investor patience. Either way, the next 12 months will make clear whether this IPO momentum translates into competitive advantage. For a closer view on potential PBM and formulary reactions, see RxPBM.ai.
